3 takeaways from a European obesity scientific meeting
BioPharma DiveJonathan GardnerOctober 1, 2026
Eli Lilly impressed with its amylin-Zepbound combination data. Elsewhere, Novo demonstrated continued weight loss following a switch to oral and AbbVie and Boehringer gave glimpses into their contenders.